Literature DB >> 10453497

[Study on the effect of ofloxacin and tanshinone II A on human leukocyte chemotactic migration in vitro].

Z Zhou1, J Zheng, W Xu.   

Abstract

In order to verify the possible anti-inflammatory activity and their potency of ofloxacin and Tanshinone II a, the effects of different concentrations of ofloxacin, Tanshinone II a and hydrocortisone on human leukocyte migration in vitro were investigated employing agarose migration technique in which f-Met-Lea-Phe was served as chemotactic factor. The results showed that all the three agents could inhibit migration of leukocytes remarkably. The effects were concentration-dependent with excellent linear relationship. The IC50 were: Tanshinone II a 0.46 microgram/ml, ofloxacin 0.63 microgram/ml, and hydrocortisone 46.52 micrograms/ml respectively. The results indicated that Tanshinone II a was the most potent agent for inhibiting migration of human leukocytes in vitro and the hydrocortisone was relatively less potent.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 10453497

Source DB:  PubMed          Journal:  Zhongguo Yi Xue Ke Xue Yuan Xue Bao        ISSN: 1000-503X


  3 in total

1.  Cryptotanshinone inhibits chemotactic migration in macrophages through negative regulation of the PI3K signaling pathway.

Authors:  M-J Don; J-F Liao; L-Y Lin; W-F Chiou
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

2.  Cryptotanshinone targets tumor-initiating cells through down-regulation of stemness genes expression.

Authors:  Ying Zhang; Stephanie M Cabarcas; J I Zheng; Lei Sun; Lesley A Mathews; Xiaohu Zhang; Hongsheng Lin; William L Farrar
Journal:  Oncol Lett       Date:  2016-04-15       Impact factor: 2.967

3.  The potential utility of acetyltanshinone IIA in the treatment of HER2-overexpressed breast cancer: Induction of cancer cell death by targeting apoptotic and metabolic signaling pathways.

Authors:  Mounia Guerram; Zhen-Zhou Jiang; Bashir Alsiddig Yousef; Aida Mejda Hamdi; Hozeifa Mohamed Hassan; Zi-Qiao Yuan; Hou-Wei Luo; Xiong Zhu; Lu-Yong Zhang
Journal:  Oncotarget       Date:  2015-09-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.